Navigation Links
Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
Date:4/26/2013

AMSTERDAM, April 26, 2013 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS) announced today the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the Amsterdam Life Science Cluster.

Under the direction of Richard Ogden , PhD, Chief Scientific Officer, and Christopher Meenan , MBA, MS, Executive Vice President of Product Manufacturing and Development, Cannabis Science, has begun initial preclinical pharmacological characterization, including pharmacokinetics, pharmacodynamics, concentration analysis, chemical structure characterization, and in vitro and in vivo extrapolation (IVIVE), as well as other essential studies that will be performed by contract manufacturing organizations utilizing proprietary strains of cannabinoids possessing properties characterized by peer reviewed literature indicating clinical attributes including inhibition of the genomic expression of HIV-associated Kaposi's Sarcoma (KS).

In conjunction with maturing Collaborative Research and Development Agreements (CRADAs) under review by academic centers associated with Members of the Company's Scientific Advisory Board, the data from these unprecedented investigations will allow for reproducible data on medicinal characteristics, pharmacogenetics and biology of the endocannabinoid activity in virologic oncology for submission to regulatory authorities in the U.S. and Europe under the supervision of Ron Sekura , PhD, Executive Vice President of Regulatory Affairs, Cannabis Science.

Robert Melamede , PhD, CEO of Cannabis Science, said, "The past 12 months, characterized by presentations at the XIX International AIDS Conference, ASA Medical Cannabis conference and other scientific meetings, and appointments of
'/>"/>

SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
2. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
3. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. New Study Shows Cannabis Effects on Driving Skills
6. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
7. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... SCOTTSDALE, Ariz. and WASHINGTON, June 15, 2011 The ... and CAQH CORE ® (Committee on Operating Rules ... collaborate on activities related to harmonizing electronic data interchange ... NCPDP and CAQH CORE began exploring the ...
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that it has received U.S. Food and Drug ... AFX™ Endovascular AAA System, for the treatment of abdominal ... Annual Meeting of the Society for Vascular Surgery (SVS), ...
Cached Medicine Technology:NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3Endologix Announces FDA Approval of AFX™ Endovascular AAA System 2Endologix Announces FDA Approval of AFX™ Endovascular AAA System 3
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am ... subsequent archived replay of the Company’s presentation may be accessed via the investor relations ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 ... Lava Springs, California’s northernmost and among its least visited State Parks. The volcanic ... whose main outflow is at Ahjumawi Lava Springs, part of the Fall River ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from ... rooms in recent years, according to the American Dental Association. According to a study ... visits went from 1.1 million in a single year to 2.2 million a year. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... decline by 39 percent, according to market research compiled for the National Association ... the U.S. Department of Labor, Bureau of Labor Statistics. As the number of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... 16 HLTH Corporation,(Nasdaq: HLTH ) today announced ... ended September 30, 2007 at approximately 4:00 pm (ET) ... announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. (Nasdaq: ... financial results for the three months ended September 30,2007 ...
... Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ASV) today ... $62 million for the third,quarter of 2007 compared ... quarter,of 2006. As previously announced, Aspreva will ... 2007. The Company will hold a conference,call and ...
... from yogurt(TM) in an easy-to-swallow caplet., VANCOUVER, ... launch of AccuFlora Pro-Biotic Acidophilus, a combination of,five ... and,supports a healthy immune system with the good ... to MayoClinic.com, there is growing public and scientific,interest ...
... of G&D, Dr. Michael Cleary (Stanford University School of ... critical player in the establishment of leukemia stem cells, ... leukemia (MLL) is a distinctive type of leukemia ... by the presence of a break and rearrangement of ...
... CHICAGO, Oct. 16 The Cambridge Group, a ... Carrie Shea,principals of the firm. Mr. Miller ... and,industry experience to The Cambridge Group. In his ... improvements in senior,executive and consulting positions. In his ...
Cached Medicine News:Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Northwest Natural Products Introduces AccuFlora(R) 2Health News:The Cambridge Group Names Two New Principals 2
... Designed To Be Used With The Gills ... On The Cornea For Making Limbal Relaxing Incisions., ... The Gills Nomograms. 6mm & 8mm Chord Length ... Relaxing Incisions.5mm Inner Circle Assists In Sizing A ...
... This System Is Designed To Manually Dilate ... Efficacy. The Bimanual Technique Maximizes Safety By ... Parallel, Rather Than Perpendicular, To The Plane ... Risk Of Inadvertent Capsule Tears. Pupil Stretching ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture.,Open ... Unobstructed Around-The-Clock Access To The Globe ...
Medicine Products: